Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dis-Chem PharmaciesJSE:DCP +0.75%86 EV-to-EBITDA is 16.17 as of Aug. 20, 2026, which is 28% above its 10-year median of 12.60. GuruFocus rates JSE:DCP with a GF Score™ of 86/100 and a GF Value™ of R38.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Dis-Chem Pharmacies ranks worse than 68.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dis-Chem Pharmacies's enterprise value is R31,511 Mil.
Dis-Chem Pharmacies's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was R1,949 Mil. Therefore, Dis-Chem Pharmacies's EV-to-EBITDA for today is 16.17.
The historical rank and industry rank for Dis-Chem Pharmacies's EV-to-EBITDA or its related term are showing as below:
JSE:DCP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.63 Med: 12.6 Max: 32.35
Current: 16.17
During the past 13 years, the highest EV-to-EBITDA of Dis-Chem Pharmacies was 32.35. The lowest was 8.63. And the median was 12.60.
JSE:DCP's EV-to-EBITDA is ranked worse than 68.23% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.76
vs JSE:DCP: 16.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dis-Chem Pharmacies's PE Ratio (TTM) for today is calculated as:
Dis-Chem Pharmacies's share price for today is R29.58.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dis-Chem Pharmacies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 was R1.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Dis-Chem Pharmacies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dis-Chem Pharmacies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dis-Chem Pharmacies EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dis-Chem Pharmacies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dis-Chem Pharmacies's EV-to-EBITDA falls into.
Dis-Chem Pharmacies's current Enterprise Value is R31,511 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dis-Chem Pharmacies's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was R1,949 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dis-Chem Pharmacies (JSE:DCP) has a EV-to-EBITDA of 16.17 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dis-Chem Pharmacies. This is 28% above median its historical median of 12.60. Over the past decade, Dis-Chem Pharmacies' EV-to-EBITDA has ranged from 8.63 to 32.35. According to the industry distribution chart, Dis-Chem Pharmacies ranks #350 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 68.2%.
Is Dis-Chem Pharmacies' EV-to-EBITDA too high?
Dis-Chem Pharmacies' current EV-to-EBITDA of 16.17 is 28% above median its 10-year median of 12.60. Over the past 10 years, this metric has ranged from a low of 8.63 to a high of 32.35. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.76. Dis-Chem Pharmacies' value of 16.17 is 50.3% above this industry median. Based on the distribution chart, Dis-Chem Pharmacies ranks #350 out of 513 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dis-Chem Pharmacies has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dis-Chem Pharmacies' EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dis-Chem Pharmacies ranks #350 out of 513 companies for EV-to-EBITDA. This places Dis-Chem Pharmacies in the lower half of its industry. The industry median EV-to-EBITDA is 10.76. Dis-Chem Pharmacies' value of 16.17 is 50.3% above this benchmark. Historically, Dis-Chem Pharmacies' own EV-to-EBITDA has ranged from 8.63 to 32.35 over the past decade. While the company's 10-year median is 12.60 vs. the industry median of 10.76, Dis-Chem Pharmacies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.76, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dis-Chem Pharmacies's current EV-to-EBITDA of 16.17 is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dis-Chem Pharmacies. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dis-Chem Pharmacies's current EV-to-EBITDA is 16.17, which is 28% above median its own 10-year median of 12.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dis-Chem Pharmacies stock overvalued right now?
Based on GuruFocus' analysis, Dis-Chem Pharmacies (JSE:DCP) is currently considered Modestly Undervalued. The stock's GF Value™ is R38.57, compared to a current price of R29.58 — trading 23.3% below its estimated fair value. The current EV-to-EBITDA is 16.17, which is 28% above median its 10-year median of 12.60 and 50.3% above the Healthcare Providers & Services industry median of 10.76. Dis-Chem Pharmacies' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dis-Chem Pharmacies (JSE:DCP), the current EV-to-EBITDA is 16.17 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dis-Chem Pharmacies (JSE:DCP) Overvalued in 2026?
Based on GuruFocus' analysis, Dis-Chem Pharmacies stock appears to be undervalued.
The current stock price of R29.58 is trading 23.3% below its estimated GF Value™ of R38.57.
GuruFocus considers Dis-Chem Pharmacies to be Modestly Undervalued.
Key valuation signals for JSE:DCP:
EV-to-EBITDA: 16.17 (28% above median its 10-year median of 12.60)
GF Value™: R38.57 vs. price of R29.58 (23.3% below fair value)
Industry Position: 50.3% above the Healthcare Providers & Services median (#350 of 513)
No single metric tells the full story. See the JSE:DCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dis-Chem Pharmacies Ltd is a pharmaceutical company based in South Africa. Its product portfolio includes personal care products, beauty products, healthcare and nutrition products, and dispensary and baby care products. The operating segments of the group are Retail and Wholesale. It derives maximum revenue from the Retail segment, which includes company stores, retailers of pharmaceuticals and a variety of health and beauty products, as well as pharma-logistic services and oncology and retailers of pharmaceutical products. The Wholesale segment consists of the CJ wholesale and company distribution businesses, wholesalers of pharmaceuticals, and a variety of health and beauty products. Geographically, the group carries out its business operations principally in South Africa.
86GF Score
Get the complete analysis for JSE:DCP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:DCP has been successfully added to your 
